Clinical Trial Update: Utilising CTC Counts to Optimize Systemic Therapy of Metastatic Prostate Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial on using circulating tumor cell counts to optimize systemic therapy for metastatic prostate cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Adenocarcinoma
• Prostate Cancer

Snippet

Sponsor: Institute of Cancer Research, United Kingdom | Conditions: Adenocarcinoma of the Prostate | Phase 3 | Status: TERMINATED